Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

15.0%

3 terminated/withdrawn out of 20 trials

Success Rate

70.0%

-16.6% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

29%

2 of 7 completed trials have results

Key Signals

3 recruiting2 with results

Enrollment Performance

Analytics

Phase 1
5(38.5%)
Phase 2
5(38.5%)
N/A
3(23.1%)
13Total
Phase 1(5)
Phase 2(5)
N/A(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (20)

Showing 20 of 20 trials
NCT05057702Not ApplicableRecruiting

Individualized Treatment Plan in Children and Young Adults With Relapsed Medulloblastoma and Ependymoma

Role: collaborator

NCT06182163Not ApplicableCompleted

Reduce Sedentary Time in Acute Lymphoblastic Leukemia

Role: collaborator

NCT06946680Phase 1Not Yet Recruiting

IL-8 Receptor-modified CD70 CAR T Cell Therapy in CD70+ Newly Diagnosed and Recurrent Pediatric High-grade Glioma (pHGG) and Newly Diagnosed Diffuse Intrinsic Pontine Glioma (ndDIPG)

Role: collaborator

NCT02425904Phase 2Active Not Recruiting

Study of Clofarabine in Patients With Recurrent or Refractory Langerhans Cell Histiocytosis and LCH-related Disorders

Role: collaborator

NCT00760656Recruiting

Establishment of a Lifetime of Cohort of Adults Surviving Childhood Cancer

Role: collaborator

NCT04742751Phase 2Active Not Recruiting

An Open-Label Pilot Intervention Trial to Prevent Diabetes in Prediabetic Adult Survivors of Childhood Cancer

Role: collaborator

NCT02868268Active Not Recruiting

Neuroblastoma Precision Trial

Role: collaborator

NCT04995003Phase 1Recruiting

HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma

Role: collaborator

NCT03971799Phase 1Active Not Recruiting

Study of Anti-CD33 Chimeric Antigen Receptor-Expressing T Cells (CD33CART) in Children and Young Adults With Relapsed/Refractory Acute Myeloid Leukemia

Role: collaborator

NCT02457845Phase 1Completed

HSV G207 Alone or With a Single Radiation Dose in Children With Progressive or Recurrent Supratentorial Brain Tumors

Role: collaborator

NCT02098512Phase 1Unknown

Immunotherapy Following Reduced Intensity Conditioning and Allogeneic Stem Cell Transplant for Poor Risk CD30+ Hodgkin Lymphoma Patients

Role: collaborator

NCT04773197Not ApplicableTerminated

Evaluating a Tailored Cognitive Behavioral Therapy for Adolescent and Young Adult Cancer Patients

Role: collaborator

NCT02747576Completed

Social Cognition and Brain Integrity in Survivors of Pediatric Medulloblastoma

Role: collaborator

NCT03468075Phase 2Terminated

Gemcitabine Plus Ascorbate for Sarcoma in Adults

Role: collaborator

NCT02926612Unknown

Pathogen Identification in Pediatric Hematopoietic Stem Cell Transplant Patients With Suspected Lower Respiratory Tract Infection

Role: collaborator

NCT01701492Completed

Cognitive, Academic and Psychosocial Functioning in Long-Term Survivors of Pediatric Stem Cell Transplantation

Role: collaborator

NCT02974569Completed

Improving Symptom Self-management in Adolescents & Young Adults With Cancer

Role: collaborator

NCT01385787Completed

MRD Testing Before and After Hematopoietic Cell Transplantation for Pediatric Acute Myeloid Leukemia

Role: collaborator

NCT01772953Phase 2Completed

Treosulfan/Fludarabine/Low Dose TBI as a Preparative Regimen for Children With AML/MDS Undergoing Allo HCT

Role: collaborator

NCT02338050Phase 2Terminated

Moxetumomab Pasudotox (CAT-8015, HA22) in Children With B-lineage Acute Lymphoblastic Leukemia and Minimal Residual Disease Prior to Allogeneic Hematopoietic Stem Cell Transplantation

Role: collaborator

All 20 trials loaded